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Abstract: COVID-19 can cause important sequels in the respiratory system and frequently presents 
loss of strength, dyspnea, polyneuropathies and multi-organic affectation. Physiotherapy interven-
tions acquire a fundamental role in the recovery of the functions and the quality of life. Regarding 
the recovery phases after hospital discharge, the current evidence available is very preliminary. 
Telerehabilitation is presented as a promising complementary treatment method to standard phys-
iotherapy. The main objective of this research is to evaluate the effectiveness of a personalized tele-
rehabilitation intervention after discharge from hospital for the improvement of functional capacity 
and quality of life compared to a program of health education and/or care in a rehabilitation center. 
As secondary objectives, to identify the satisfaction and perception of patients with the telerehabil-
itation intervention and the presence of barriers to its implementation, as well as to evaluate the 
cost-effectiveness from the perspective of the health system. This study protocol will be carried out 
through a single blind multicenter randomized clinical trial in the south of Spain. We hypothesize 
that the implementation of a telerehabilitation program presents results not inferior to those ob-
tained with the current standard intervention. If the hypothesis is confirmed, it would be an oppor-
tunity to define new policies and interventions to address this disease and its consequences. Trial 
registration NCT04742946. 




Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes corona-
virus disease 2019 (COVID-19). On March 11, 2020, COVID-19 was categorized as a pan-
demic and its outbreak was declared a public health emergency of international concern 
[1–3]. Current reports estimate that 80% of cases are asymptomatic or mild; 15% of 
cases are severe (infection requiring oxygen supply); and 5% are critical patients re-
quiring ventilation and life support [2,4–6]. The average time from symptom onset to 
recovery is two weeks when the illness is mild; and three to six weeks when it is severe 
or critical. It should be noted that between 75%–80% of hospitalized patients will be ad-
mitted to hospital for a long period of time (±21 days) [7]. 
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COVID-19 can cause important sequelae in the patient after the virus has been over-
come, one of the main ones being respiratory system involvement by bilateral pneumonia. 
Loss of strength, dyspnea, polyneuropathy and multiorgan involvement (liver, myocar-
ditis and even brain damage) are also common [5,8,9]. Consequently, physiotherapy is 
playing a vital role in this pandemic and will be fundamental in improving the health of 
many of the patients. Recent studies already indicated a loss of pulmonary capacity of 
between 20% and 30% [10]. Therefore, it is a multiorgan disease with a wide and hetero-
geneous range of sequelae, the extent of which is not yet known [11]. 
1.1. Physiotherapy in Patients with COVID-19 
Physiotherapy has a very important role in the functional recovery of patients with 
COVID-19, both at the respiratory and motor levels in their different phases of evolution 
[12]. International studies and expert consensus begin to draw the roadmap for physio-
therapists in the different stages of coronavirus both for patients in intensive care units 
and during their hospital stay on the ward [13], defining the available evidence on each 
modality of intervention [14]. An international group of experts in cardiorespiratory phys-
iotherapy met to urgently develop a clinical practice guideline in the approach of physio-
therapy to COVID-19. The group focused mainly on case management interventions in 
the acute hospital phase where rehabilitation intervention is essential to limit severity and 
promote early functional recovery [14]. Research has pointed out the indispensability of 
providing physiotherapy services including weekends and holidays [15]. 
With respect to the recovery phases, discharge from hospital and subsequent con-
finement for up to 14 days, according to health recommendations, the data currently avail-
able are preliminary [16]. In this recovery and discharge phase, two types of patients are 
differentiated: 
For patients with a mild-moderate respiratory process, the short-term goal will be to 
gradually restore physical and psychological condition with a series of aerobic exercise 
guidelines to restore pre-hospital exercise capacity [16]. 
For patients with a severe/critical process, the evidence indicates that at the time of 
discharge patients with COVID-19 may experience physical deconditioning, dyspnea sec-
ondary to exercise and muscular atrophy among other sequelae [17,18]. In these patients 
with a severe/critical process, the main physiotherapy interventions will be based on: pa-
tient education, aerobic exercise, strength and training exercises, secretion drainage and 
ventilatory techniques, if the patient’s clinical manifestations so require, exercises aimed 
at strengthening the peripheral muscles, changes in position and remaining active when-
ever possible and when the situation of clinical stability permits [17,18]. 
1.2. Telerehabilitation 
This term is used to describe the provision of rehabilitation services at a distance, 
using communication technologies [19]. An expanded definition includes applications 
such as consultation, home care, monitoring, therapy and patient self-care that are pro-
vided in various locations including the home, community, health services and the work-
place [20,21]. 
In addition to traditional physical therapy, studies based on telerehabilitation pro-
grams have published results of effectiveness, validity, non-interference and important 
advantages in some neurological, cognitive, musculoskeletal and respiratory disorders, 
providing an opportunity to define new policies and social interventions [22]. There is a 
growing interest in the use of technology for respiratory health interventions [23]. Telere-
habilitation offers an alternative approach that can better meet the needs of patients with 
airway and lung impairments especially in terms of ease of access and elimination of 
travel [24] and in the case of COVID-19 by limiting their possible transmission by avoiding 
human-to-human contact. 
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Currently, health systems are immersed in a continuous process of innovation to im-
prove the effectiveness of health services [25,26]. Telerehabilitation is presented as a prom-
ising complementary treatment method to standard physiotherapy, providing physio-
therapy support at any time and in any place, both in the health field, community envi-
ronment, and the home in several pathologies [27,28]. It has also been stated that the high 
viability and acceptability of this technology can be satisfactory to obtain an improvement 
in the quality of life of patients [29]. 
Although it is still too early to state with a high level of evidence the consequences of 
COVID-19 on functional capacity, the need to implement pulmonary rehabilitation pro-
grams in these patients is based in evidences in similar pathophysiology [30–32]. 
The main objective of this research is to evaluate the effectiveness of a personalized 
telerehabilitation intervention in patients diagnosed with COVID-19 after discharge from 
hospital for the improvement of functional capacity and quality of life compared to a pro-
gram of health education and/or care in a rehabilitation center. As secondary objectives, 
to identify the satisfaction and perception of patients with the telerehabilitation interven-
tion and the presence of barriers to its implementation, as well as to evaluate the cost-
effectiveness from the perspective of the health system. The hypothesis of this research is 
that the implementation of a telerehabilitation (TR) program in patients with COVID-19 
presents no inferior results in the improvement of functional capacity and quality of life 
compared to those obtained with a health education program and/or care in a rehabilita-
tion center. 
2. Material and Methods 
This research is carried out by means of a single blind multicenter randomized clini-
cal trial in patients residing in Andalucía (south of Spain) with a COVID-19 diagnosis who 
have been discharged from hospital. This research uses the guidelines on Standards for 
Quality Improvement and Excellence in Reporting (SQUIRE) [33] and will be carried out 
in accordance with CONSORT (Consolidated Standards of Reporting Trials) criteria [34].  
A Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) checklist 
is provided as Additional file 1, and the flow diagram for the study protocols is included 
as Figure 1. 
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Figure 1. Study design. 
2.1. Patients 
The study includes adults diagnosed with COVID-19 with mild-moderate and se-
vere-critical respiratory processes who have been treated in hospitals in (south of Spain) 
and who have been discharged from hospital. The fundamental ethical precepts according 
to the Helsinki Declaration [35] and Law 14/2007 of 3 July on Biomedical Research will be 
respected, guaranteeing the protection and confidentiality of data. This trial has the ap-
proval of the Andalucía Ethics Committee with HIP version 281020. Patients in the study 
are required to read and approve the consent form. 
Patients must reside or stay in the Andalucía (south of Spain) during the intervention 
phase, have computer technology with an Internet connection at home (including one of 
the following devices: desktop personal computer, laptop, tablet or smartphone), and be 
able to access e-mail or WhatsApp frequently and reliably. Patients who are not in full 
cognitive capacity to use new technology tools will be excluded. 
For the development of this research, an intentional non-probabilistic type of sam-
pling will be used for the convenience of the study, due to the characteristics of the sub-
jects. 
A sample size of (n = 237) with a proportional distribution for each arm of the study 
(group TR = 118 + control group = 117) with an expected proportion of losses (R = 15%) 
and a confidence index IC = 95% was used. 
Patients are recruited from hospitals rehabilitation and physiotherapy departments. 
















People with or recovering from COVID-19, recruited from 
Andalusian Hospitals, with recommendation to start 













Experimental Group: (TR) 
Telerehabilitation Intervention (on a 
daily basis) 
Control Group: Standard of care 
(Rehabilitation Program in Hospital-Primary 
care center or health education program at 
home, (on a daily basis) 
Baseline measurement: 1-min STS 
test, SPPB test, SF-12, EQ-5D 
Post-intervention measurement: after 
4 and 8 weeks (1-min STS test, 
SPPB test, SF-12, EQ-5D, TSUQ, 
Direct Cost,) 
Intervention: 8 weeks Intervention: 8 weeks 
Baseline measurement: 1-min STS test, 
SPPB test, SF-12, EQ-5D 
Post-intervention measurement: after 4 and 
8 weeks (1-min STS test, SPPB test, SF-12, 
EQ-5D, TSUQ, Direct Cost,) 
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sample include the multidisciplinary collaboration of south of Spain hospitals, heads of 
rehabilitation services and Physiotherapist teams. The collaborators will be informed 
about the characteristics of the study in personal interviews and presentation of the pro-
ject. Patient recruitment seeks to ensure socio-demographic diversity in relation to social 
origin, gender, ethnicity and education adapted to the particularities of the reference pop-
ulation in Andalucía and prior information on compliance with data protection laws. We 
will try to make sure that the sample data are homogeneous at the beginning of the study, 
trying not to have significant differences in demographic, medical and other variables. 
2.2. Randomization and Single Blinding 
Before patient inclusion, a research secretary will generate the allocation sequence 
and randomly assign patients consecutively with opaque sealed numbered envelopes. A 
computerized random number generator will be used. The research secretary will be in-
structed not to reveal the allocation sequence to any of the research team. The nature of 
the intervention in both groups does not allow blinding of patients and physiotherapists. 
It is therefore a single-blind study, where the evaluator does not know the nature of the 
intervention. 
Study subjects are randomly assigned to either the TR group or the control group 
through a computerized randomization system. Subjects receive an initial evaluation 
based on clinical parameters and follow-up discharge reports. Data will be collected by 
an evaluator and integrated into research databases. 
2.3. Intervention 
The TR group receives a personalized program for 8 weeks, including at least one 
session per day and is done through a web and mobile application. The telerehabilitation 
application allows health professionals to create personalized exercise programs, hold 
video conferences with patients, generate videos, images and parameters of each exercise, 
as well as send them by email and follow up patients through the mobile application. 
The TR program describes the exercises to be performed, the number of series and 
repetitions, and the criteria for progression, which will be based on the clinical guidelines 
published for patients with COVID-19 and described in the introduction section. The 
Physiotec software was selected by the research team to be best suited to the needs of the 
patients. 
Patients are initially supervised by the research team who will conduct training ses-
sions to ensure proper execution of the exercises and encourage patient adherence. Pa-
tients will be instructed to perform self-training by following the video exercises through 
the TR program, as well as a support document called COVID-19 Patient Telerehabilita-
tion Manual. The number of synchronous sessions (1 to 1) via videoconference will be 
determined by the initial evaluation, limiting the interventions to 1 session per day of 
maximum 45–50 min, always adapted to the previous evaluation and to the needs of each 
patient. 
Patients will be advised to refrain from any other specific training during the inter-
vention period. Any deviation from the adherence and practice of the TR program is rec-
orded on a daily basis, noting any adverse incidents. 
Telerehabilitation and physical therapy interventions may include aerobic training—
generate exercise patterns such as walking, fast walking, jogging, swimming, etc., starting 
at a low intensity and duration and increasing gradually; 20–30 min of session duration is 
recommended, 3–5 sessions/week, although it will always depend on the sensation of fa-
tigue and/or dyspnea that each patient presents [18]. Progressive strength training is rec-
ommended working 1–3 muscle groups with a load of 8–12 repetitions, with 2-min train-
ing intervals. The frequency would be 2–3 sessions/week for a minimum period of 6 
weeks, increasing the load by 5%–10%/week [18]. Secretion drainage or ventilatory tech-
niques to re-educate the respiratory pattern, improve ventilation, mobilize the thorax and 
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favor secretion drainage, especially in those patients with chronic pathology prior to 
COVID-19 or who have a reduced pulmonary capacity to cause the disease [36]. 
Due to the lack of detailed knowledge of sequelae, a correct evaluation of each par-
ticular case is recommended before applying physiotherapeutic techniques [16]. The soft-
ware and the mobile application for such intervention are provided and financed by ex-
clusive license by the principal researcher. Customized exercise program examples are 
available at main author request. 
The control group (CG) receives the standard of care recommended for patients dis-
charged from hospital. Based on the individual needs of each subject, it consists of a reha-
bilitation program in their hospital or primary care center of reference, in the event that 
they present evidence of immunity and the evaluation of the sequelae requires it. If you 
do not present proof of immunity or if you test positive for COVID-19, you will receive a 
recommendation for confinement for a minimum of 14 days and a health education pro-
gram to be carried out at home where recommendations for the care of health sequelae 
are included. 
2.4. Outcome Measures 
The initial assessment includes a self-made clinical interview for anamnesis con-
ducted via videoconference. 
2.4.1. Affiliation Data and Socio-Demographic Questionnaire 
Including age, gender, location and other socio-demographic variables. 
2.4.2. Main Explanatory Variable 
Functional Capacity: for the evaluation of the functional capacity and fragility of the pa-
tients the following tests will be performed 
Firstly, the “sit-to-stand test in 1 min” (1-min sit-to-stand, STS). This assessment of 
functional capacity in patients with respiratory impairment is an excellent alternative to 
the 6-min walk test (6MWT) which has certain limitations with regard to the space re-
quirements for its execution. The 1-min STS test is a reliable, valid, and responsive test for 
measuring functional exercise capacity in patients with airway impairment and elicited a 
physiological response comparable to that of the 6MWT [37]. To carry out this test, the 
standardized protocol described by Crook and collaborators [37] will be used. 
Secondly, the short performance physical battery test (SPPB). This is a widely used 
and validated test battery with high internal consistency, which evaluates three points: 
walking speed with the 4-m walk test; strength and resistance of the lower limbs by count-
ing the time required to perform 5 squats (sit-to-stand test), and balance by standing with 
feet together, in tandem and semi-tandem. Each item is evaluated with a score from 0 to 
4. The maximum final score is 12. An outline and protocol of the test execution is presented 
at Figure 2 [35]. 
Quality of Life: 
The SF-12 and EuroQoL-5d questionnaires will be used for the assessment of health-
related quality of life. 
The SF-12 questionnaire is the short version of the SF-36, presenting good correlation 
and being considered an adequate instrument of choice to measure the general health sta-
tus of the population [38]. The SF-12 questionnaire assesses eight dimensions of health-
related quality of life: physical function, physical role, body pain, general health, vitality, 
social function, emotional role and mental health [39]. The EuroQoL-5D assessment 
questionnaire (EQ-5D) contains a descriptive system of one’s health status measured 
in five dimensions (mobility, self-care, activities of daily living, pain and anxiety/de-
pression). The EQ-5D has a visual analogue scale (VAS) that assesses the state of 
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health “today” with scores ranging from 0 (worst imaginable health) to 100 (best im-
aginable health). With the EQ-5D questionnaire, information is obtained on the level 
of the problem (no problem, some/moderate problem or severe problem [39]. 
 
 
Figure 2. Short performance physical battery test (SPPB) based on Riskowski JL et al. 
2.4.3. Secondary Explanatory Variable  
Satisfaction and usability  
The acceptance and usability of telemedicine applications is a prerequisite for iden-
tifying the potential clinical benefits of this technology. It is therefore important to com-
plement this research with tools that examine patient satisfaction and perception [40]. An 
adaptation of the Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ), whose 
psychometric analysis supports construct validity and internal consistency reliability and 
which is available in English and Spanish will be used [40]. The instrument used showed 
high reliability (Cronbach’s alpha 0.8) and evidence of validity with respect to perception 
in telemedicine [41]. Includes 17 questions that are assessed with a 5-point Likert subjec-
tive scale (1 totally disagree and 5 completely agree). The individual obtains scores from 
17 to 85. The higher the score, the better the perception of the telerehabilitation interven-
tion. Therefore each of the scores of the 17 variables indicated and finally the total score 
of the Test will be analyzed [40,41]. 
Analysis of the Cost-Effectiveness 
To assess the cost-effectiveness of the telerehabilitation intervention, the interna-
tional guidelines for conducting cost analyses in randomized clinical trials will be fol-
lowed [42]. Such an economic analysis is based on the health sector perspective, which 
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means that only costs corresponding to health interventions will be considered, and not 
related costs to the patient. Therefore, only costs related to the provision of health services 
will be taken into account [43]. 
Costs are divided into two categories of variables: firstly, costs related to clinical as-
pects (direct costs) and secondly, costs related to the use of the technology (indirect costs). 
Direct Costs: Numerical variable calculated on the basis of the number of hours of 
intervention and the cost of the Physiotherapist according to the hourly wage in force in 
the health system in the centers where the research is carried out. It will be calculated 
based on the recording of the number of sessions in both groups. 
Indirect Costs: Numerical variable calculated based on the cost of using the technol-
ogy for the telerehabilitation platform. 
2.5. Data Collection Procedure and Statistical Analysis 
Once the study subjects have been informed, data will be collected for statistical 
analysis. The procedure to register different outcomes will be performed at baseline T.0 
(Pre), at 4 weeks after the start of the intervention T.1 (Post1), and 8 weeks when the in-
tervention ends T.2 (Post). Schedule of enrollment, interventions, and assessments is 
shown in Table 1. Initial evaluation (Pre) and measures at four and eight weeks (Post 
1 and Post 2) will be carried out by an evaluator at the headquarters designated for this 
purpose, facilitating the access of the patient and after confirmation of the appointment 
by the research secretary or by means of telecommunication tools that allow the realiza-
tion of the different measuring instruments. 
Table 1. Schedule of enrolment, interventions, and assessments. 
 Enrolment Allocation Post Allocation Close Out 








ENROLMENT:      
Eligibility screen X     
Informed consent  X     
Advance info X     
Allocation  X    
INTERVENTION:      
TR Group       
Control Group       
ASSESMENT:      
Baseline Variables X     
Initial Assesment  X    
STS Test  X X X X 
SPPB test.  X X X X 
SF-12 and EQ-5D  X X X X 
TSUQ   X X X 
Direct Costs    X X X 
Data Collection      
Statistical Análisis     X 
The data will be added to the database created for this purpose and managed by the 
principal researcher using exportable data tables for statistical analysis. Each of the par-
ticipating subjects will be assigned a study participation number, and the results of each 
of the variables analyzed will be collected. The principal investigator will be in charge of 
the anonymization of the data, so that the data will be recorded by eliminating the link 
with the identifiable person. 




The results of the research will be presented as a summary of the outcome measures, 
together with the estimated effect size and its precision. The statistical analysis will be 
performed according to the intention-to-treat principle using SPSS software. 
The filiation data of the participating subjects will be presented by means of fre-
quency tables and histograms. A descriptive statistical analysis of the different variables 
will be carried out with frequency tables, bars and sectors in order to have as much infor-
mation as possible for exploration and analysis. The homogeneity of the sample will be 
analyzed and normality tests will be performed. 
The results are evaluated by comparing the differences between the groups with 
mixed linear model and T-test statistics to test the hypothesis that the means of two groups 
are or are not significantly different from each other. 
3. Discussion 
The development of this study could facilitate the creation of future clinical guide-
lines on the use of physical therapy through telerehabilitation platforms in the public 
health field. 
The need to treat these patients in the short, medium and long term after discharge 
from hospital is an unavoidable commitment for the society that must assess the socio-
economic impact and persevere in the search for effective interventions. This situation of 
world crisis is presented as an opportunity to continue developing professionally and sci-
entifically, to implement the advantages offered by new technologies in the field of tele-
rehabilitation, as well as to seek opportunities to solve the possible shortcomings of the 
Health Systems. 
The current questions about the effects caused by COVID-19 should not limit us to 
act—on the contrary, it should stimulate the search for solutions that can bring pulmonary 
rehabilitation closer to patients who need it after discharge from hospital. In this sense, 
telerehabilitation is seen as a tool that could provide an efficient and cost-effective re-
sponse to the health problems identified [12]. Physiotherapy will play a fundamental role, 
not only in the intensive care units and in the hospitalized patients, but it will also be a 
cornerstone in the interdisciplinary health team for the recovery of the sequelae which 
should lead to an improvement in the quality of life of patients with COVID-19 [12]. 
Telemedicine has the promise of improving quality, increasing patient access and 
reducing health care costs [44]. Studies have shown that telerehabilitation is effective in 
improving clinical outcomes in various pathologies suggesting that the increased inten-
sity provided by telerehabilitation is a promising option to be offered to patients [27]. Re-
cent research concludes that telerehabilitation appears to be a viable option for selected 
hospitalized patients with COVID-19 and may be a safe way of delivering inpatient reha-
bilitation to isolated or at-risk populations [45]. Although a recent systematic review in-
dicates that telerehabilitation may be safe and feasible and may lead to reduced face-to-
face rehabilitation therapy; in addition, remote rehabilitation assessment should be con-
sidered during the COVID-19 pandemic [46]. Another important fact is that the reported 
number of adverse events was low, and most studies reported that the average session 
adherence rate was >70% [46]. 
Unlike other studies that require software implementations in specific devices, our 
intervention generates few obstacles since it is available in any device that allows internet 
connection and that patients usually have (personal computer, laptop, tablet, smartphone) 
allowing access from any location and different devices. This contrasts with other studies 
that require a highly complex technological platform, software installation and multidi-
rectional cameras for controlled clinical control connecting the healthcare provider and 
the patient [47]. As the patient uses his own technological devices, the rapid implementa-
tion process is guaranteed. This, however, may lead to a selection bias for those patients 
without access to technology. Technical problems (disconnection, device failures) and 
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technological difficulties may arise in connection with the use of technology. However, 
staff members will be available to provide technical support to patients by phone or email, 
without the need to visit the patient at home to install or check any hardware. 
The lack of improvement and positive evolution of the patient, as well as the appear-
ance of a low level of adherence was considered as possible adverse events. Also is con-
sidered as an adverse event, the performance of movements with excessive workload that 
cause muscle overload. 
Patients will be informed of the importance of warning the healthcare professional 
of any incident or setback in their recovery, as well as their right to withdraw from par-
ticipation in the research at any time. 
4. Conclusions 
This research should provide knowledge about the possibility of implementing TR 
programs in patients with COVID-19 after discharge from hospital, identifying health re-
sources and allocated costs that will allow the definition of new intervention policies in 
this group of patients. 
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